Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 2022 Dec 26;72(5):1183. doi: 10.1007/s00262-022-03342-x

Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model

Tianyun Qiao 1,2,#, Jinbo Zhao 2,#, Xiangbing Xin 2,#, Yanlu Xiong 2, Wenwen Guo 3, Fancheng Meng 2, Hui Li 3, Yangbo Feng 1,2, Hui Xu 4,✉, Changhong Shi 3,✉, Yong Han 1,✉
PMCID: PMC10110673  PMID: 36571598

Correction to: Cancer Immunology, Immunotherapy 10.1007/s00262-022-03318-x

In the online published article, the affiliation details for Authors Tianyun Qiao, Yangbo Feng and Yong Han were given as:

Department of Thoracic Surgery, Air Force Specialty Medical Center, Fourth Military Medical University, Xi’an 710032, China

but should have been

Department of Thoracic Surgery, Air Force Medical Center, Beijing 100142, China

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Tianyun Qiao, Jinbo Zhao and Xiangbing Xin have contributed equally to this work.

Contributor Information

Hui Xu, Email: xubz@fmmu.edu.cn.

Changhong Shi, Email: changhong@fmmu.edu.cn.

Yong Han, Email: hanyong_td@163.com.

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES